Who We Are?
We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47.
DOS47 – Confirmed Mechanism of Action
Our Technology
Wah Wong (left) analysing protein expression data using the Guava® flow cytometer and Baomin Tian (right) analysing images of protein samples in SDS-PAGE gel on Bio-Rad Gel Doc™ XR+ system.
Baomin Tian removing unreacted reagents from a protein conjugation reaction solution with a G20 desalting column.
Wah Wong checking the growth of tumor cell culture under the microscope.
.
Iain Wilson replacing a check valve on the Acquity UPLC, part of the Waters Xevo G2QTof mass spectrometer system
Wah Wong pipetting culture medium into a 96-well tissue culture plate inside a biological safety cabinet.
Baomin Tian analysing mass spectrometry data, mapping peptides from protein samples, on a Waters UNIFI workstation.
Iain Wilson streaking a LB-kanamycin agar plate with E. coli cells that were transformed with plasmid DNA inside a biological safety cabinet.
Wah Wong (left) analysing protein expression data using the Guava® flow cytometer.